Processing...
Clinical Trials for Non-Small Cell Lung Cancer
Search
Search
There are 415 active trials for advanced/metastatic non-small cell lung cancer.
Click on a trial to see more information.
415 trials meet filter criteria.
Sort by:
TrialFetch AI summary: This trial enrolls previously treated patients with unresectable locally advanced, recurrent, or metastatic NSCLC, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, or left-sided colorectal cancer; prior treatment with a topoisomerase I inhibitor–payload ADC is excluded. All participants receive ALX2004, an investigational EGFR-targeting antibody–drug conjugate with a topoisomerase I inhibitor payload, at a dose determined by the study stage.
ClinicalTrials.gov ID: NCT07085091
TrialFetch AI summary: Adults with measurable, locally advanced or metastatic KRAS-mutant or KRAS-amplified solid tumors who have no remaining standard treatment options or have declined them receive oral AMG 410, a reversible pan-KRAS inhibitor, alone or with the PD-1 inhibitor pembrolizumab. Patients with colorectal or pancreatic cancer may receive AMG 410 with the EGFR-targeting antibody panitumumab.
ClinicalTrials.gov ID: NCT07094113
TrialFetch AI summary: Patients with incurable locally advanced, recurrent, or metastatic solid tumors who lack appropriate standard treatment receive once-daily oral CP-383, an investigational dual DHODH/TEAD4 inhibitor. Dose expansion focuses on selected cancers, including colorectal, small-cell lung, and head and neck cancers, with some cohorts defined by tumor alterations.
ClinicalTrials.gov ID: NCT07030257
TrialFetch AI summary: Adults with measurable advanced bladder, lung, head and neck, esophageal, or pancreatic cancer and ECOG 0–1 receive intravenous PF-08046876, an antibody–drug conjugate targeting integrin beta-6 that delivers a camptothecin-class topoisomerase I inhibitor. Dose escalation requires progression after standard therapy; dose optimization and expansion cohorts allow up to two prior systemic therapy lines for advanced disease.
ClinicalTrials.gov ID: NCT07090499
TrialFetch AI summary: Adults with advanced or metastatic NSCLC, SCLC, endometrial cancer, or triple-negative breast cancer who have received or declined standard therapy, or have no standard options, receive IV LY4175408. This investigational antibody–drug conjugate targets PTK7 and delivers exatecan, a topoisomerase I inhibitor.
ClinicalTrials.gov ID: NCT07046923
TrialFetch AI summary: Adults with progressing advanced or metastatic CLDN1-positive colorectal, intrahepatic cholangiocarcinoma, squamous non-small cell lung, urothelial, or cervical squamous cancers after standard systemic therapy receive intravenous ALE.P03 monotherapy. ALE.P03 is an investigational CLDN1-targeted antibody–drug conjugate that delivers exatecan, a topoisomerase I inhibitor, to CLDN1-expressing cells.
ClinicalTrials.gov ID: NCT07169734
TrialFetch AI summary: Adults with measurable advanced or metastatic solid tumors who have exhausted standard treatment options or have no standard therapy receive intravenous TJ101, a bispecific antibody-drug conjugate targeting EGFR and B7-H3, every 21 days. Prior topoisomerase I inhibitor treatment is excluded.
ClinicalTrials.gov ID: NCT07181473
TrialFetch AI summary: Patients with previously treated, progressive advanced or metastatic colorectal adenocarcinoma, non-small cell lung cancer, or pancreatic ductal adenocarcinoma who have no tolerable standard treatment options receive intravenous PHN-012, an investigational antibody–drug conjugate. Its target antigen and payload have not been disclosed.
ClinicalTrials.gov ID: NCT07127874
TrialFetch AI summary: Patients with advanced or metastatic MUC-1–overexpressing solid tumors after standard therapy receive M0324 alone or with pembrolizumab; the pembrolizumab cohort also requires progression on or after prior checkpoint inhibition. A separate cohort with previously untreated metastatic pancreatic ductal adenocarcinoma receives M0324 plus mFOLFIRINOX. M0324 is an investigational MUC-1 × CD40 bispecific antibody designed to activate immune cells near MUC-1–expressing tumors.
ClinicalTrials.gov ID: NCT07166601
TrialFetch AI summary: Adults with unresectable locally advanced or metastatic HCC, ECOG 0–1, and Child-Pugh A liver function receive ZW251, an investigational glypican-3–targeting antibody–drug conjugate that delivers a topoisomerase I inhibitor payload. The study evaluates escalating and recommended doses for safety and preliminary antitumor activity.
ClinicalTrials.gov ID: NCT07164313